Vaccine Adjuvants Market Report 2025

The vaccine adjuvants market size has grown strongly in recent years. It will grow from $1.89 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increasing vaccine development, prevalence of infectious diseases, government initiatives and immunization programs, research and development investments, globalization of vaccine distribution.

The vaccine adjuvants market size is expected to see strong growth in the next few years. It will grow to $2.83 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to pandemic preparedness, expanding vaccine portfolio, global immunization goals, collaborations and partnerships, focus on therapeutic vaccines. Major trends in the forecast period include advancements in adjuvant technologies, focus on immunogenicity enhancement, combination adjuvants for enhanced effectiveness, demand for safer and well-tolerated adjuvants, personalized vaccines and adjuvants.

The forecast of 8.9% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade disputes may burden U.S. immunization programs by increasing prices of aluminum salt formulations and novel immunostimulants imported from the UK and Belgium, potentially compromising vaccine efficacy and raising preventive medicine costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth of the vaccine adjuvants market is expected to be driven by the increasing prevalence of infectious diseases. Infectious diseases encompass infections caused by viruses, bacteria, fungi, or parasites. Vaccines play a crucial role in treating various infectious diseases such as hepatitis B (HBV), hepatitis C (HCV), HIV, malaria, syphilis, and brucellosis. As per the 2022 World Health Organization (WHO) report, approximately 10.6 million people globally were infected with tuberculosis in 2021, resulting in 1.6 million deaths, and 1.5 million individuals contracted HIV, with 650,000 losing their lives to it. Hence, the rising prevalence of infectious diseases is expected to be a key driver for the vaccine adjuvants market.

The expected growth of the vaccine adjuvants market is also anticipated to be fueled by the increasing funding for vaccine research activities. Vaccine research activities encompass comprehensive scientific endeavors focused on developing, testing, and enhancing vaccines to prevent infectious diseases. These research activities play a crucial role in identifying, testing, and optimizing potential adjuvant candidates derived from diverse sources, including natural products, synthetic compounds, and even bacteria or viruses. For example, in October 2023, the United States Department of Health and Human Services, a US-based provider of essential human services, announced Project NextGen, involving a $500 million investment to initiate the development of Phase 2b clinical trial plans and cutting-edge technologies for next-generation vaccination and treatment platforms. Consequently, the increasing funding for vaccine research activities is a driving force behind the growth of the vaccine adjuvants market.

Product innovations are becoming a significant trend in the vaccine adjuvants market. Companies in this field are focusing on adopting innovative solutions to enhance their market positions. For example, in December 2022, Evonik Industries, a Germany-based chemical manufacturing company, launched PhytoSquene, a plant-based squalene derived from amaranth oil. This sustainable alternative to traditional shark-derived squalene is intended for use in vaccine adjuvants and other pharmaceutical applications, improving vaccine efficacy by enhancing immune responses. The introduction of PhytoSquene highlights the increasing emphasis on sustainability within the pharmaceutical industry.

Prominent companies operating in the vaccine adjuvants market are concentrating on introducing innovative products, such as plant-based squalene, to gain a competitive advantage. Plant-based squalene, derived from the herbaceous plant amaranth (Amaranthus caudatus), offers a sustainable and cruelty-free alternative to traditional squalene obtained from shark liver oil. For instance, in December 2022, Evonik Industries AG, a specialty chemicals company based in Germany, launched PhytoSquene, a plant-based squalene utilized in adjuvants to enhance vaccine efficacy. This product has applications in adjuvants for parenteral vaccines, with potential expansion into other pharmaceutical and cosmetic uses. PhytoSquene addresses the needs of patients who, due to cultural or religious beliefs, cannot use products derived from animals.

In August 2022, GSK plc, a pharmaceutical and biotechnology company based in the UK, completed the acquisition of Affinivax Inc. for a deal amount of $3.3 billion. This acquisition bolsters GSK's strategy to establish a substantial portfolio of specialized novel drugs and vaccines. It includes a next-generation 24-valent pneumococcal vaccine adjuvant (AFX3772), based on the groundbreaking Multiple Antigen Presenting System (MAPSTM) platform technology, currently in phase II development. Affinivax Inc. is a clinical-stage biopharmaceutical company based in the UK operating in the vaccine adjuvant market.

Major companies operating in the vaccine adjuvants market include GlaxoSmithKline Plc., Novavax Inc., SPI Pharma Inc., Agenus Inc., CSL Limited, InvivoGen Limited., Brenntag Biosector A/S, Adjuvatis, Merck KGaA, Croda International Plc, Seppic Inc, OZ Biosciences, Avanti Polar Lipids Inc, Astellas Pharma Inc, Virometix AG, MPV Technologies Limited, Adjuvance Technologies Inc., Novartis AG, Vaxine Pty Ltd, SBI Biotech Co. Ltd., Statens Serum Institute, GSK Vaccines, VaxLiant LLC, VaxForm LLC, Serum Institute of India, Dynavax Technologies Corporation, Vaxcyte Inc., VBI Vaccines Inc., Medicago Inc., Aphios Corporation.

North America was the largest region in the vaccine adjuvants market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global vaccine adjuvants market report during the forecast period. The regions covered in the vaccine adjuvants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vaccine adjuvants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The vaccine adjuvants market research report is one of a series of new reports that provides vaccine adjuvants market statistics, including the vaccine adjuvants industry's global market size, regional shares, competitors with a vaccine adjuvants market share, detailed vaccine adjuvants market segments, market trends, and opportunities, and any further data you may need to thrive in the vaccine adjuvants industry. This vaccine adjuvants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vaccine adjuvants refer to compounds or components included in vaccines to enhance the body's immune response to antigens that lack immunostimulatory capabilities, thereby creating a more robust immune reaction.

The primary categories of vaccine adjuvants include adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and others, such as saponin-based adjuvants. Adjuvant emulsions are defined as mixtures of two or more typically immiscible liquids. These vaccine adjuvants are administered through various routes, including oral, intramuscular, intranasal, subcutaneous, and intradermal, in both human and veterinary settings. They are employed in the treatment of conditions such as cancer, infectious diseases, and other ailments, including zoonotic diseases.

The vaccine adjuvants market consists of sales of adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and saponin-based adjuvants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.